Astragalus-containing traditional Chinese medicine, with and without prescription based on syndrome differentiation, combined with chemotherapy for advanced non-small-cell lung cancer: A systemic review and meta-analysis

Current Oncology

Volumn 23, Issue 3, 2016, Pages e188-e195

  Wang, S F ^a,b,c   Wang, Q ^c   Jiao, L J ^c   Huang, Y L ^a,b   Garfield, D ^d   Zhang, Jie ^a,b,c   Xu, Ling ^c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Advanced non small cell lung cancer; Astragalus; Chemotherapy; TCM

Indexed keywords

AIDI; BO ER NING; CAMPTOTHECIN DERIVATIVE; CHINESE DRUG; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; HERBACEOUS AGENT; JINFUKANG DECOCTION; KANGAI; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM; SHENQI FUZHENG; UNCLASSIFIED DRUG; VINBLASTINE; ZHEN QI FU ZHENG;

ADVANCED CANCER; ANEMIA; APPETITE DISORDER; ASTRAGALUS (PLANT); CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHINESE MEDICINE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; KARNOFSKY PERFORMANCE STATUS; META ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

EID: 84974603457     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.23.2920     Document Type: Review

References (34)

1. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220–41. [Erratum in: CA Cancer J Clin 2012;62:348]
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin 2014;64:9–29. [Erratum in: CA Cancer J Clin 2014;64:364]
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:60–90.
4. Xing J, Zhang Y. Experience of treatment purely with Chinese medicine in elderly patients with advanced non-small-cell lung cancer: 10 cases [Chinese]. Cancer Prev Res 2013;40:. [Available online at: http://www.cnki.com.cn/Article/CJFD Total-ZLFY201301008.htm; cited 21 April 2016]
5. Astragalus membranaceus. Monograph. Altern Med Rev 2003,8:73–7.
6. Yoshida Y, Wang MQ, Liu JN, Shan BE, Yamashita U. Immunomodulating activity of Chinese medicinal herbs and Oldenlandia diffusa in particular. Int J Immunopharmacol 1997;19:359–70.
7. Lau BH, Ruckle HC, Botolazzo T, Lui PD. Chinese medicinal herbs inhibit growth of murine renal cell carcinoma. Cancer Biother 1994;9:153–61.
8. McCullough M, See C, Shu XJ, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced nonsmall-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 2006;24:419–30.
9. Tierney F, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
10. Moher D, Pham B, Jones A, et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609–13.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.
12. Zintzaras E, Ioannidis JP. Heterogeneity testing in metaanalysis of genome searches. Genet Epidemiol 2005;28:123–37.
13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.
14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997;315:629–34.
15. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.
16. Liu J. Clinical observation of Jin Fukang oral liquid in the treatment of non-small cell lung cancer [Chinese]. Tradit Chin Med 1997;:727–9. [Available online at: http://www. cnki.com.cn/Article/CJFDTotal-ZZYZ199712011.htm; cited 21 April 2016]
17. Liu J. Clinical observation on the Yifei Kangliu decoction treatment of 271 patients with non-small cell lung cancer [Chinese]. Shanghai Zhong Yi Yao Za Zhi 2001;:. [Available online at: http://www.cnki.com.cn/Article/CJFDTOTAL -SHZZ200102000.htm; cited 21 April 2016]
18. Liu W. Clinical observation concerning Boer Ning capsules combined with hep regimen in the treatment of elderly patients with advanced non-small cell lung cancer [Chinese]. Chinese J Clin Oncol 2004;:. [Available online at: http://d. wanfangdata.com.cn/Periodical/zgzllc200416018; cited 21 April 2016]
19. Luo X, Yin Q, Ma T. Clinical observation of the np regimen combined with Ai Di injection in the treatment of non-small cell lung cancer [Chinese]. Cancer Prev Treat 2005;12:543–4. [Available online at: http://www.cnki.com.cn/Article/CJFDTotal-QLZL200507021.htm; cited 21 April 2016]
20. Lv X. Clinical study on the treatment of non-small cell lung cancer with integrated traditional Chinese and Western medicine [Chinese]. Mod Oncol 2005;:117–19. [Available online at: http://www.cnki.com.cn/Article/CJFDTotal-SXZL200506057.htm; cited 21 April 2016]
21. Luo SZ, Long J, Yu X. Clinical observation of Shenqi Fuzheng injection combined with paclitaxel plus cisplatin in the treatment of advanced non–small cell lung cancer [Chinese]. Clinical Cancer Research 2006;:181–3. [Available online at: http://www.cnki.com.cn/Article/CJFDTotal-ZLYJ200603013. htm; cited 21 April 2016]
22. Luo S. Clinical observation of Shenqi Fuzheng injection combined with paclitaxel and cisplatin in the treatment of nonsmall cell lung cancer [Chinese]. Journal of Clinical Oncology 2007;:381–2. [Available online at: http://www.cnki.com.cn/Article/CJFDTotal-LCZL200705024.htm; cited 21 April 2016]
23. Fan Q. Ai Di combined with vinorelbine and cisplatin in the treatment of advanced non–small cell lung cancer [Chinese]. Chinese Journal of Modern Medicine 2008;:36–8. [Available online at: http://www.cnki.com.cn/Article/CJFDTotal-ZHTY200808020.htm; cited 21 April 2016]
24. Xu X, Ge W, Yuan G. Effects of Ai Di injection on vinorelbine plus cisplatin chemotherapy for advanced non–small cell lung cancer [Chinese]. De Guo Yi Xue 2008;7:560–3. [Available online at: http://www.cnki.com.cn/Article/CJFDTotal-ZDLZ200810005.htm; cited 21 April 2016]
25. Zhang Y, Wang H. Ai Di combined with gcb regimen in the treatment of advanced non–small cell lung cancer [Chinese]. Liaoning College of Traditional Chinese Medicine 2008;:73–4. [Available online at: http://www.cnki.com.cn/Article/CJFDTotal-LZXB200803043.htm; cited 21 April 2016]
26. Zhang M. Clinical observation on the effect of Zhenqi Fuzheng capsule combined with docetaxel plus cisplatin in the treatment of advanced non–small cell lung cancer [Chinese]. Modern Oncology 2009;:1102–3. [Available online at: http://www.cnki.com.cn/Article/CJFDTotal-SXZL200906041.htm; cited 21 April 2016]
27. Zhao C, Yang Z. The recent curative effect observed with Ai Di injection combined with chemotherapy in the treatment of advanced non–small cell lung cancer. China Practical Medicine 2009;4:126–7. [Available online at: http://www.cnki.com.cn/Article/CJFDTotal-ZSSA200902100.htm; cited 21 April 2016]
28. Wu J, Xu ZY, Wang ZQ. Clinical study on treatment of advanced non–small cell lung cancer with kangliu zengxiao decoction [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2010;30:137–40.
29. Yang X. Clinical study of Kangai injection combined with gc regimen in the treatment of elderly patients with advanced non–small cell lung cancer [Chinese]. New Chinese Medicine 2010;:73–5. [Available online at: http://www.cnki.com.cn/Article/CJFDTotal-REND201011042.htm; cited 21 April 2016]
30. Tianjun C, Asmit T, Chen M. The clinical efficacy of gp chemotherapy combined with Zhenqi Fuzheng capsules in the treatment of nsclc [Chinese]. Materia Medica 2012;:2264–5. [Available online at: http://www.cnki.com.cn/Article/CJFDTotal-SZGY201209070.htm; cited 21 April 2016]
31. Guo L, Bai SP, Zhao L, Wang XH. Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non–small cell lung cancer: effects on quality of life and survival. Med Oncol 2012;29:1656–62.
32. Xie D, Lin Y, Li XQ, Yang AL. Clinical effects of Traditional Chinese Medicine plus gp regimen in treatment of advanced non-small cell lung cancer patients [Chinese]. Chinese Medicine 2012;30:2363–5. [Available online at: http://www.cnki.com.cn/Article/CJFDTotal-ZYHS201210077.htm; cited 21 April 2016]
33. Hsu CH, Lee CJ, Chien TJ, et al. The relationship between qi deficiency, cancer-related fatigue and quality of life in cancer patients. J Tradit Complement Med 2012;2:129–35.
34. Jiang M, Lu C, Zhang C, et al. Syndrome differentiation in modern research of traditional Chinese medicine. J Ethnopharmacol 2012;140:634–42.